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Abstract
Background: There is a strong association between cardiometabolic risk and adipose tissue dysfunction with great
consequences on type 2 diabetic patients. Visceral Adiposity Index (VAI) is an indirect clinical marker of adipose
tissue dysfunction. Gum Arabic (GA) is a safe dietary fiber, an exudate of Acacia Senegal. Gum Arabic had shown lipid
lowering effect in both humans and animals. The aim of this trial was to determine the effect of GA supplementation
on anthropometric obesity marker, Visceral Adiposity Index (VAI) and blood pressure in patients with type 2 diabetes
mellitus.
Methods: This randomized, double blinded, placebo controlled trial recruited a total of 91 type 2 diabetic patients (73
females, 18 males), age (mean ± SD) 50.09 ± 9.3 years on hypoglycemic agents and were randomly assigned into two
groups, either to consume 30 g of GA or 5 g of placebo daily for 3 months. Anthropometric obesity markers were
measured and indices were calculated. Blood pressure was measured and high density lipoprotein (HDL) and triglycerides
(TG) were determined in fasting blood samples at the start and end of the study period.
Results: After intervention, Gum Arabic decreased BMI and VAI significantly (P < 0.05) in GA group by 2 and 23.7%
respectively. Body adiposity index significantly decreased by 3.9% in GA group while there were no significant
changes in waist circumference or waist-to-hip ratio (WHR). Systolic blood pressure significantly decreased by 7.6% in
GA group and by 2.7% in placebo group from baseline with no significant changes in diastolic blood pressure in the
two groups.
Conclusion: Gum Arabic consumption at a dose of 30 g/d for 3 months may play an effective role in preventing
weight gain and modulating adipose tissue dysfunction in type 2 diabetic patients, although no effect has been
shown in waist-to-hip ratio.
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Background
The incidence of diabetes is increasing globally leading
to serious complications [1]. In Sudan, knowledge about
and awareness of diabetes is poor and that adversely
affects its control and management [2].
The use of oral hypoglycemic drugs is associated with
the tendency to gain weight or other side effects; therefore
nutritional care is crucial for diabetic patients.
Obesity and weight gain play a major role in insulin
resistance and development of diabetes. It was recog-
nized that elevated levels of triglycerides lead to elevated
levels of free fatty acids which modulate pathways that
link insulin receptors with glucose transporters and impair
normal function of beta cell. Furthermore, hyperlipidaemia
can lead to more difficulties in controlling hyperglycaemia
in diabetic patients [3]. The presence of low density
lipoprotein (LDL) particles and low HDL levels are among
the components of cardiometabolic syndrome and its risk
can be identified by elevated TG/HDL ratio [4].
In clinical practice, anthropometric measurements
such as body mass index could be a predictor for the
management of overweight or obesity in patients at high
cardiometabolic risk. Unfortunately, there is conflicting
evidence in predicting CVD in diabetic patients due to
variation in visceral adipose tissue accumulation by
many etiological factors including age, gender and ethnicity
and differences in body fat distribution and composition
[5], but generally there is a linear relationship between
BMI and cardiovascular disease.
Visceral adipose index is a good predictor of visceral
adiposity which is related to type 2 diabetes [6, 7] and
hypertension [8]. VAI is indicative of fat distribution and an
indicator of altered adipose function which is associated
with insulin resistance, an increased VAI is associated with
an increased risk of abdominal obesity, hypertriglyceridemia
and low HDL [9], and it has been proven to be superior to
other adiposity indices in predicting CVD risk [10] .
In 2011, the Body Adiposity Index (BAI) was proposed
to provide a direct estimate of percentage of body adiposity
[11]. Other simple anthropometric measurements had also
shown strong association with cardiometabolic risk [12].
Diet with high fiber prevents visceral adiposity reflected
by reduction in waist circumference and BMI [13].
Gum Arabic (GA) with its high fiber content has been
reported to improve lipid metabolism in experimental
animal studies with antioxidant effect and improving
capillary function. Consequently we postulated that
consumption of GA would lead to improvement of
anthropometric indices and blood pressure as indica-
tors of CVD. Therefore, this study was designed to
determine effects of daily intake of 30 g Gum Arabic on
anthropometric variables associated with cardiometabolic
risk among type 2 diabetes.
Methods
Study design
This was a single center, randomized, double blind,
placebo-controlled trial comparing pre and post effects
of GA versus placebo in diabetic patients who have
agreed to participate in this trial.
The trial was conducted at Academy Charity Teaching
Hospital (ACTH) in Sudan; it took place from August
2014 to February 2015. All patients had been diagnosed
with type 2 diabetes mellitus according to the criteria of
WHO [14].
The trial protocol was approved by the local ethical
committee of State of Khartoum Ministry of Health –
and it is registered under PACTR201403000785219. This
study was conducted according to the guidelines of the
Declaration of Helsinki. Informed consent was obtained
from all patients.
Outcomes
Primary outcome
The primary outcome was assessed in our previous article
which was the effect of GA on mean percent change of
fasting plasma glucose and HbA1c from baseline level [15].
Secondary outcome
Secondary outcomes included in our previous article
were changes of GA on BMI and lipid profile [15]. In this
study secondary outcomes included are obesity anthropo-
metric indexes (VAI, BAI, LAP and deep abdominal adipose
tissue (DAAT) and mean percent change of systolic and
diastolic blood pressure from baseline level.
Recruitment
Patients were recruited from diabetes clinic at ACTH,
Khartoum (Fig. 1). Those referred to the clinic were
offered the opportunity to participate in this trial. The
initial screening visit included the signing of the consent
form, filling of questionnaire, and measurement of weight,
height, waist circumference, hip circumference, blood
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pressure and blood sample for biochemical test. Patients
were instructed to fast for 10–12 h prior to their first visit.
A total of 100 type 2 diabetic patients agreed to take
part and signed the consent forms after the purpose and
instructions concerning the trial had been explained to
them. Patients with type 2 diabetes mellitus and on anti-
hyperglycemic medication with fasting plasma glucose of
(FPG) ≥7.0 mmol/L (126 mg/dl) and HbA1c ≥ 6.5% were
included.
Alcoholics or drug addicts, patients with history of gastro-
intestinal diseases or Gum Arabic allergy, type 1 diabetes
mellitus, pregnancy or planning to have a child within next
6 months and patients not eligible for the study due to
medical reason evaluated by physician were excluded [15].
Randomization and blinding
Randomization was done by series of numbers generated
by independent third-party not associated with the study.
Patients and chief attending doctor were blind to the
intervention. Supplement package of GA or placebo
(pectin) were prepared in sealed boxes. Pectin was
chosen as placebo because it is a soluble polysaccharide
with viscous sensation when dissolved in water similar
to GA. It is a good source of fiber and has been recom-
mended for diabetics.
The daily supplement was a 30 g of powdered GA
(Dar Savanna Ltd., Khartoum, Sudan) or 5 g of placebo
(Andre Pectin, Yantani, China). The high viscosity of pectin
limits consumption of it to 5 g only, 250 mL of water was
mixed well with the package content before intake. No
dietary restrictions were given and patients were asked not
to change their lifestyle or physical activities during the
study period. Patients continued taking their medications
as prescribed by the physician.
Consumption of supplements and any of adverse
reactions were examined by attending doctor. Lifestyle
Fig. 1 flowchart of study design
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and medication of each patient was checked using a
self-reporting sheet. Participants were followed weekly
and the final examination was completed after 3 months
of intervention [15].
Intervention
Of the 100 patients who were enrolled in the research,
97 were given either placebo (n = 47) or GA (n = 50).
Ninety-one completed the study, three patients violated
the instructions and were advised to discontinue; two
got pregnant and one patient had a traffic accident and
was hospitalized.
Data collection and measurements
Baseline measurements for all patients were taken, and
they included; anthropometric, blood pressure measure-
ments, blood samples for fasting plasma glucose (FPG),
HbA1c and lipid profiles, in addition to completing a
general health questionnaire. Blood samples were obtained
by venipuncture kept in cryogenic collection tubes and
were centrifuged immediately at 2700 rpm for 10 min to
separate serum from blood. The serum was used to deter-
mine lipid profile (HDL and triglyceride levels). Enzymatic
biochemical analyses were performed using (BioSystems
S.A. 310- Semi automated chemistry analyser) to deter-
mine lipid profile; HDL and LDL were analyzed by using
precipitation and cholesterol oxidase method, FPG was
analysed by using glucose oxidase method and HbA1c by
direct ion exchange method [15]. Waist circumference
was measured by using flexible, elastic measuring tape at
midpoint between the lower rib and the top of iliac crest
at the end of expiration. Hip circumference was measured
at the level of the greater femoral trochanters. The waist
circumference divided by the hip circumference gave
the (waist-to-hip ratio (WHR). Body weight (kg) was
measured on calibrated balance scale and height (cm)
was measured with standmeter to nearest 0.5 cm, BMI
was calculated as the ratio of weight in kilograms to
height in meters squared (kg/m2) [16].
Lipid accumulation product (LAP) was calculated with
the following formula: male LAP = [waist (cm)-65] X TG
(mmol/l) and female LAP = [waist (cm) -58] X TG
(mmol/l) [17], and VAI was calculated from [WC/
(39.68 + 1.88 x BMI)] x (TG/1.03) x (1.31/HDL) for men
and [WC/ (36.58 + 1.89 x BMI] x (TG/0.81) x (1.52/
HDL) for women [18].
Body Adiposity Index (BAI) was calculated by using hip
circumference and height (BAI = hip circumference (cm)
divided by (height (m)) 1.5 minus 18) [11].
Deep abdominal adipose tissue (DAAT) was calculated by
using the formula: − 382.9 + [1.09 x weight - (kg)] + [6.04 x
WC- (cm)] + (− 2.29 x BMI) for men and− 278 + [− 0.86 x
weight - (kg)] + [5.19 x WC- (cm)] for women [16].
Blood pressure (BP) was measured using mercury
sphygmomanometer.
Visceral adipose index (VAI) and blood pressure (BP)
were measured as primary outcome measures, HC, WC,
WHR, BMI, BAI, LAP, DAAT, HDL-c and triglyceride
were evaluated and measured as secondary outcomes.
These measurements were performed before and after
intervention.
Data analysis
Statistical analyses were performed using SPSS (Statistical
Package for the Social Science, IBM SPSS version 23)
values were expressed as mean ± standard deviation and
Paired sample T-Test was used to compare continuous
variables or Pearson’s chi-square test within the groups.
P < 0.05 was regarded as statistically significant.
Results
General characteristics of participants
A total of 120 patients were invited with 100 patients
identified as eligible to participate in this study, nine
patients were excluded for not meeting the project criteria.
Ultimately, a total of 97 patients were randomly assigned
to Gum Arabic or placebo group as shown in study
flowchart in Fig. 1.
Demographic data and baseline parameters
Demographic characteristics of participants and baseline
parameters are reported in Table 1. No significant differ-
ence in patient’s baseline characteristics between the two
groups (P > 0.05), however, the majority of patients were
females (80.2%).
In Table 1, cardiometabolic risk parameters including
blood pressure, smoking, physical activity and alcohol
consumption did not differ significantly by group. About
59.4% (n = 54) of patients were on combined therapy
(sulfonylureas e.g. (glimepiride and glipizide) and met-
formin) and 40.6% (n = 37) on metformin only [15].
Changes in biochemical parameters
High density lipoprotein had significantly increased by 20%
from baseline in GA group with no significant change in
placebo group. Triglycerides had not statistically changed
in both groups (Table 2).
Changes in anthropometric and indexes
Gum Arabic consumption significantly decreased weight
and hip circumferences by 2% and 2.5% respectively from
baseline level, although no significant change in waist
circumference was observed among this group (P = 0.121).
BMI had significantly decreased by 2% in GA treated
group from baseline level (P = 0.007).
Visceral adiposity index and BAI were reduced by 23.7%
and 3.9% respectively among GA group from baseline
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level. Lipid accumulation product (LAP) significantly
reduced in GA group by 14.4% from baseline level but
no significant change was observed for deep abdominal
adipose tissue (DAAT).
Changes in blood pressure
Twenty nine point nine percent of total patients were
hypertensive on hypertensive medications mainly (beta
blockers, calcium channel blockers or angiotensin
converting enzyme inhibitors) beside antidiabetic medica-
tion. Systolic blood pressure was significantly reduced in
both groups with no significant effect on diastolic blood
pressure in both groups as seen in Table 2.
Discussion
Cardiovascular diseases incidence is increased in people
with type 2 diabetes [19]. Prevention and treatment of
diabetes play a beneficial role in the delay of complica-
tions and improving quality of life in diabetic patients.
Gum Arabic is a soluble fermentable fiber has shown
hypoglycaemic, antioxidant effects and also improved
lipid metabolism in previous studies [20].
Gum Arabic showed anti-obesity effect among healthy
adults [21], and blunted weight gain in experimental
studies in animals [22]. According to our knowledge, this
is the first trial studying the effect of GA on simple
anthropometric measurements and approximate visceral
adiposity by measuring VAI and LAP among type 2 diabetic
patients. Our data showed that supplementation of GA
significantly decreased BMI among GA group with no
effect on WC. The negative effect of GA on WC might
be explained by the blotted abdomen caused by fermen-
tation of GA in colon and gases formation which might
affect WC measurement. However, BMI and WC reflects
only excess weight with poor sensitivity in diagnosing
excess body fatness and differentiation between subcuta-
neous and visceral fat compartments [23]. Therefore, an
increased WC cannot always reflect high-risk visceral fat
[24]. Individuals with different risk levels of CVD and
diabetes may have similar BMI, while their WC and
metabolic risk profiles may be different. Visceral fat is
characterized by different levels hence there is different
levels of insulin resistance [25]. It is also linked to several
pathological conditions including impaired glucose and
Table 1 Baseline characteristic and risk factors of patients in Gum Arabic and Placebo groups (n = 91)
Variables Gum Arabic (n = 46) Placebo (n = 45)
SEM SEM P value 95 % C.I of differences
Lower Upper
Age (Years) a 49.96 ± 8.73 1.29 50.22 ± 9.29 1.39 0.89 −4.02 3.49
Male b 12(26.1%) 6(26.1%) 0.19
Female b 34(73.9%) 39(86.7%)
Duration of DM (months) a 64.04 ± 55.43 8.17 59.53 ± 48.09 7.17 0.68 −17.13 26.15
Height (cm) a 162.26 ± 9.01 1.33 161.07 ± 8.82 1.31 0.52 −2.52 4.91
Weight (kg) a 72.86 ± 15.72 2.32 77.07 ± 13.84 2.06 0.18 −10.38 1.96
Waist circumferences (cm) a 98.65 ± 12.41 1.83 94.76 ± 14.9 2.22 0.18 −1.81 9.60
WHR a 0.93 ± 0.08 0.011 0.89 ± 0.10 0.015 0.08 −0.00 0.067
BMI (Kg/m2) a 27.66 ± 5.37 0.79 29.96 ± 6.54 0.97 0.07 −4.79 0.19
BAI a 33.90 ± 7.46 1.10 34.38 ± 8.65 1.29 0.77 −3.64 2.72
VAI a 3.17 ± 2.29 0.34 2.08 ± 1.55 0.23 0.01 0.24 2.00
DAAT,cm2 a 190.92 ± 70.88 10.45 153.65 ± 67.37 10.04 0.01 5.61 62.90
LAP,cm.mmol/l a 61.28 ± 39.46 5.81 41.65 ± 32.86 4.90 0.01 2.66 36.58
SBP (mmHg) a 131.74 ± 16.37 2.43 128.44 ± 14.45 2.19 0.312 −3.14 9.73
DBP (mmHg) a 80.00 ± 9.89 1.42 78.22 ± 8.87 1.35 0.148 −2.14 5.69
TG (mmol/l) a 1.54 ± 0.63 0.093 1.10 ± 0.54 0.08 0.00 0.156 0.72
HDL(mmol/l) a 1.10 ± 0.39 0.058 1.15 ± 0.39 0.059 0.57 −0.22 0.12
Hypertension b 14(30.4%) 6(13.3%) 0.07
Smoking b 5(10.9%) 2(4.4%) 0.43
Exercise this year b,c 3(6.5%) 2(4.4%) 0.66
Alcohol consumption b 2(4.3%) 2(4.4%) 0.98
Values are presented as a Mean ± SD, b number (percentage) [15]
Abbreviations: BMI Body Mass Index, SBP Systolic Blood Pressure DBP Diastolic Blood Pressure
c Exercise in year 2014 to 2015
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lipid metabolism and insulin resistance [26, 27]. Visceral
fat also determines cardiovascular risk profile and increases
the susceptibility of arterial hypertension [28]. Previous
study by Glover et, al (2009) reported that intake of dietary
fiber, including GA was associated with a significant fall in
mean systolic blood pressure [SBP] in normal individuals
who neither had hypertension nor diabetic [29]. In the
current study there was significant reduction of [SBP] by
7.6% from baseline level within GA group vs. 2.7% reduc-
tion in placebo group and there was insignificant reduction
of [DBP] in both groups. In this work about 30% of GA
patients were hypertensive compared to 13% in placebo
group as a result of the randomization; this created a
difficulty in assessing the effect of GA on the mean
blood pressure in this study. Lipid accumulation product
(LAP) is associated with diabetes, predicting CVD and
metabolic diseases better than WC and BMI [17]. Our
data showed significant decrease of VAI and LAP in GA
group, such VAI and LAP are calculated with WC, BMI,
triglyceride and HDL. In this study there was a decrease
in blood triglyceride by 11% which may have a positive
effect on a glucose metabolism, as high triglyceride
interferes with insulin level and actions [30]. The obtained
reduction in VAI and the significant increase in HDL level
can possibly improve glucose homeostasis by different
mechanisms and enhance insulin sensitivity [31]. Gum
Arabic itself is reported to reduce TNFa expression in
visceral adipose tissues of female mice and its production
is linked to obesity-insulin resistance [32].
The dyslipidaemia in patients with type 2 diabetes (high
triglyceride and low HDL-C levels) presents a major risk
of cardiovascular disease. Since this was decreased by GA
intake in addition to the improvement in body mass
composition we can claim that GA can be a beneficial
supplementation in diabetic type 2 patients [30].
Conclusions
The findings of this study demonstrated that GA con-
sumption in a dose of 30 g /day was effective in weight
reduction and modulating adipose tissue dysfunction in
type 2 diabetic patients. This was reflected by the increase
in HDL and decrease of triglyceride which were major
component in assessing the CV risk factors in diabetic
patients.
Abbreviations
11β-HSD1: 11β-hydroxysteroid dehydrogenase type I; BAI: Body adiposity
index; BMI: Body mass index; BP: Blood pressure; DAAT: Deep abdominal
adipose tissue; GA: Gum Arabic; HDL: High-density lipoprotein; LAP: Lipid
accumulation product; LDL: Low-density lipoprotein; TG: Triglycerides;
TNFa: Tumor necrosis factor alpha; VAI: Visceral adiposity index; WC: Waist
circumference; WHR: Waist to hip ratio
Acknowledgments
The authors would like to thank participants and investigators in study
group. Special thanks to Dr.Ahmed Dirar for his cooperative work as
consultant physician in this study and we are grateful to Dar Savanna Ltd
(safest), Sudan for providing Gum Arabic (Acacia Senegal) powder.
Funding
Financial support for this study was provided by University of Medical
Sciences and Technology (UMST) and Organization for Women in Science
for the Developing World (OWSD)/ (TWAS).
Availability of data and materials
The datasets used and analysed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
Concept development and study design: RB, AMS. Collection of samples and
biochemical analysis: RB. Follow-up and generation of ideas: RB, KE, MBK,
AMS. Analysis and interpretation of data: KE, RB. Critical revision of the manu-
script: MBK, AMS, RB. Drafting and revision of the manuscript: RB, KE, MBK,
AMS. All authors approved the final version of manuscript for submission.
Ethics approval and consent to participate
The trial is in accordance with the Declaration of Helsinki and guidelines
from the Sudanese State of Khartoum Ministry of Health Ethical Committee.
Approval was obtained by local research ethics committee ‘Institutional
Review Board at University of Medical Science and Technology (UMST); SUM
116 -IRB number: 00008867’ .The study was carried out and informed written
consent was obtained from all patients before their enrolment.
Consent for publication
Not applicable.
Competing interests
The authors declare that there are no competing interests regarding the
publication of this paper.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Physiology, Faculty of Medicine, University of Medical
Sciences & Technology, Khartoum, Sudan. 2Graduate Entry Medical School,
University of Limerick, Limerick, Ireland. 3Human Biology & Research
Laboratory Manager, School of Medicine, Royal College of Surgeons in
Ireland RCSI-Bahrain, P.O Box 15503, Adliya, Manama, Bahrain. 4Department
of Physiology, Faculty of Medicine, University of Khartoum, P.O Box 102,
Khartoum, Sudan.
Received: 1 January 2018 Accepted: 13 March 2018
References
1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes
mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med.
1998;15(7):539–53.
2. Mohamed Ahmed A, Hassan AN. Diabetes mellitus in Sudan: the size of the
problem and the possibilities of efficient care. Pract Diabetes. 2001;18(9):324–7.
3. Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of
adipokines and the relationship between obesity, inflammation, insulin
resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci.
2014;15(4):6184–223.
4. Salazar MR, Carbajal HA, Espeche WG, Aizpurúa M, Maciel PM, Reaven GM.
Identification of cardiometabolic risk: visceral adiposity index versus
triglyceride/HDL cholesterol ratio. Am J Med. 2014;127(2):152–7.
5. Tchernof A, Després J-P. Pathophysiology of human visceral obesity: an
update. Physiol Rev. 2013;93(1):359–404.
6. Du T, Sun X, Huo R, Yu X. Visceral adiposity index, hypertriglyceridemic
waist and risk of diabetes: the China health and nutrition survey 2009. Int J
Obes. 2014;38(6):840.
Babiker et al. Lipids in Health and Disease  (2018) 17:56 Page 7 of 8
7. Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C.
Visceral adiposity index (VAI) is predictive of an altered adipokine profile in
patients with type 2 diabetes. PLoS One. 2014;9(3):e91969.
8. Stępień M, Stępień A, Banach M, Wlazeł RN, Paradowski M, Rizzo M, Toth PP,
Rysz J. New obesity indices and adipokines in normotensive patients and
patients with hypertension: comparative pilot analysis. Angiology. 2014;
65(4):333–42.
9. Schuster J, Vogel P, Eckhardt C, Dal Bosco Morelo S. Applicability of the
visceral adiposity index (VAI) in predicting components of metabolic
syndrome in young adults. Nutricion hospitalaria. 2014;30(4):806-812.
10. Numan Ahmad M, Halim Haddad F. Suitability of visceral adiposity index as
a marker for cardiometabolic risks in Jordanian adults. Nutricion hospitalaria.
2015;32(6):2701-2709.
11. Bergman RN, Stefanovski D, Buchanan TA, Sumner AE, Reynolds JC, Sebring NG,
Xiang AH, Watanabe RM. A better index of body adiposity. Obesity. 2011;19(5):
1083–9.
12. Goh LG, Dhaliwal SS, Welborn TA, Lee AH, Della PR. Anthropometric
measurements of general and central obesity and the prediction of
cardiovascular disease risk in women: a cross-sectional study. BMJ Open.
2014;4(2):e004138.
13. Du H, Boshuizen HC, Forouhi NG, Wareham NJ, Halkjær J, Tjønneland A,
Overvad K, Jakobsen MU, Boeing H, Buijsse B. Dietary fiber and subsequent
changes in body weight and waist circumference in European men and
women. Am J Clin Nutr. 2010;91(2):329–36.
14. Consultation WHO. Definition, diagnosis and classification of diabetes
mellitus and its complications. In. Part. 1999;25.
15. Babiker R, Elmusharaf K, Keogh MB, Banaga AS, Saeed AM. Metabolic effect
of gum Arabic (Acacia Senegal) in patients with type 2 diabetes mellitus
(T2DM): randomized, placebo controlled double blind trial. Funct Foods
Health Dis. 2017;7(3):222–34.
16. Wang Z, Hoy W. Waist circumference, body mass index, hip circumference
and waist-to-hip ratio as predictors of cardiovascular disease in aboriginal
people. Eur J Clin Nutr. 2004;58(6):888.
17. Kahn HS. The “lipid accumulation product” performs better than the body
mass index for recognizing cardiovascular risk: a population-based
comparison. BMC Cardiovasc Disord. 2005;5(1):26.
18. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo
A. Visceral adiposity index. Diabetes Care. 2010;33(4):920–2.
19. Raza JA, Movahed A. Current concepts of cardiovascular diseases in
diabetes mellitus. Int J Cardiol. 2003;89(2):123–34.
20. Ali BH, Ziada A, Blunden G. Biological effects of gum arabic: a review of
some recent research. Food Chem Toxicol. 2009;47(1):1–8.
21. Babiker R, Merghani TH, Elmusharaf K, Badi RM, Lang F, Saeed AM. Effects of
gum Arabic ingestion on body mass index and body fat percentage in
healthy adult females: two-arm randomized, placebo controlled, double-
blind trial. Nutr J. 2012;11(1):111.
22. Ahmed AA, Musa HH, Fedail JS, Sifaldin AZ, Musa TH. Gum arabic decreased
visceral adipose tissue associated with downregulation of 11β-
hydroxysteroid dehydrogenase type I in liver and muscle of mice. Bioact
Carbohydr Diet Fibre. 2015;6(1):31–6.
23. Kruschitz R, Wallner-Liebmann SJ, Hamlin MJ, Moser M, Ludvik B, Schnedl WJ,
Tafeit E. Detecting body fat–a weighty problem BMI versus subcutaneous fat
patterns in athletes and non-athletes. PLoS One. 2013;8(8):e72002.
24. Després J-P, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodés-
Cabau J, Bertrand OF, Poirier P. Abdominal obesity and the metabolic
syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb
Vasc Biol. 2008;28(6):1039–49.
25. Sam S, Haffner S, Davidson MH, D'agostino RB, Feinstein S, Kondos G, Perez A,
Mazzone T. Hypertriglyceridemic waist phenotype predicts increased visceral
fat in subjects with type 2 diabetes. Diabetes Care. 2009;32(10):1916–20.
26. Ritchie S, Connell J. The link between abdominal obesity, metabolic
syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;
17(4):319–26.
27. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y,
Vasan RS, Murabito JM, Meigs JB, Cupples LA. Abdominal visceral and
subcutaneous adipose tissue compartments. Circulation. 2007;116(1):39–48.
28. Onat A, Avci G, Barlan M, Uyarel H, Uzunlar B, Sansoy V. Measures of
abdominal obesity assessed for visceral adiposity and relation to coronary
risk. Int J Obes. 2004;28(8):1018.
29. Glover DA, Ushida K, Phillips AO, Riley SG. Acacia (sen) SUPERGUM™ (gum
Arabic). An evaluation of potential health benefits in human subjects. Food
Hydrocoll. 2009;23(8):2410–5.
30. Parhofer KG. Interaction between glucose and lipid metabolism: more than
diabetic dyslipidemia. Diabetes Metab J. 2015;39(5):353–62.
31. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL
in glucose metabolism. Nat Rev Endocrinol. 2012;8(4):237–45.
32. Ushida K, Hatanaka H, Inoue R, Tsukahara T, Phillips GO. Effect of long term
ingestion of gum arabic on the adipose tissues of female mice. Food
Hydrocoll. 2011;25(5):1344–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Babiker et al. Lipids in Health and Disease  (2018) 17:56 Page 8 of 8
